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Evolution of the neurochemical profile consisting of 19 metabolites after 30 mins of middle cerebral
artery occlusion was longitudinally assessed at 3, 8 and 24 h in 6 to 8 lL volumes in the striatum
using localized 1H-magnetic resonance spectroscopy at 14.1 T. Profound changes were detected as
early as 3 h after ischemia, which include elevated lactate levels in the presence of significant
glucose concentrations, decreases in glutamate and a transient twofold glutamine increase, likely to
be linked to the excitotoxic release of glutamate and conversion into glial glutamine. Interestingly,
decreases in N-acetyl-aspartate (NAA), as well as in taurine, exceeded those in neuronal glutamate,
suggesting that the putative neuronal marker NAA is rather a sensitive marker of neuronal viability.
With further ischemia evolution, additional, more profound concentration decreases were detected,
reflecting a disruption of cellular functions. We conclude that early changes in markers of energy
metabolism, glutamate excitotoxicity and neuronal viability can be detected with high precision non-
invasively in mice after stroke. Such investigations should lead to a better understanding and
insight into the sequential early changes in the brain parenchyma after ischemia, which could be
used for identifying new targets for neuroprotection.
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Introduction
Experimental models of ischemia help advance
the understanding of the pathobiology of cerebral
ischemia and thus may lead to the identification of
potential therapeutic targets for neuroprotection. In
stroke patients, magnetic resonance (MR) techniques,
mostly MR imaging (MRI) applications, play a
central role in diagnosis, monitoring the lesion
progression and the outcome after therapeutic inter-
ventions. Perfusion- and diffusion-weighted MRIs
are used for diagnosis in the acute phase, followed by
T2-weighted images to locate the lesion and the
associated edema at later time points (Weber et al,
2006; and references therein). Magnetic resonance
spectroscopy (MRS) provides powerful applications,
such as MRS imaging (MRSI) for tissue characteriza-
tion (Weber et al, 2006; and references therein).
Although diffusion MRI is widely used in the
clinical setting, understanding the neurochemical
profile of ischemic brain injury can shed light on
important mechanisms and on the evolution of
ischemic lesions and thus provide insights into
processes linked to glutamatergic excitotoxicity and
neuronal damage in experimental animal models
(Coon et al, 2006). Moreover, MRS has capabilities of
assessing information other than water in tissue, for
example, 1H-MRS of metabolites using their specific
protons (Berkelbach van der Sprenkel et al, 1988),
31P-MRS of energy phosphate metabolism (Kozlowski
et al, 1997) or 13C-MRS of metabolic alterations
(van der Zijden et al, 2008).
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In vivo MRS studies of ischemia, especially
1H-MRS, have been limited so far to a few com-
pounds, mainly lactate (Lac), total creatine (phos-
phocreatine + creatine, PCr + Cr), total choline
(glycerophosphocholine + phosphocholine, GPC +
PCho) and total N-acetyl-aspartate (N-acetyl-aspar-
tate + N-acetyl-aspartyl-glutamate, NAA + NAAG) in
animal models (Coon et al, 2006; Hesselbarth et al,
1998; Igarashi et al, 2001; Kuhmonen et al, 1994;
Malisza et al, 1998) and to a certain extent in humans
(Cheong et al, 2006; Nitkunan et al, 2006). This could
be explained by the variability of most ischemic
models and further compounded by limitations in
the MR methodology, notably the use of lower
magnetic field strengths. With improved MR techni-
ques, more than 18 metabolites, termed ‘the neuro-
chemical profile’, have been identified in rats (Rao
et al, 2007), including the neuronal marker NAA
(Clark, 1998); some mostly cell-specific metabolites,
such as glutamine (Gln) and glutamate (Glu), are
present mainly in astrocytes and neurons, respec-
tively (Ottersen et al, 1992; Torp et al, 1991); the
osmoregulator taurine (Tau) (Ottersen et al, 1992;
Torp et al, 1991); and energy substrates, such as
glucose (Glc) and Lac. Although the neurochemical
profile has been analyzed in a transgenic mouse
model of Huntington’s disease (Tka´cˇ et al, 2007), to
our knowledge the neurochemical profile of cerebral
ischemia has not been studied in mice, possibly due
to the combination of technical challenges inherent
in their small size and in the spatial resolution of the
available MR equipment.
Therefore, the aim of this study was to establish
reliable and precise hallmarks of early metabolic
changes after ischemia. Metabolic changes were
characterized using a horizontal bore 14.1-T MR
system in a mouse model of transient cerebral
ischemia, which induces highly reproducible striatal
lesions. We expect that this study will lay the
foundation for a description of the cellular biologic
status, thereby providing an additional ‘fingerprint’
of disease progression, which can be monitored for
diagnosis and to determine the effects of specific




All experiments were approved by the local authority. In
this study, a transient 30-mins of MCAO was chosen for the
consistent lesion in the striatum 1 day after ischemia
(preliminary data not shown). Briefly, 11 male ICR-CD1
mice (24±3 g, Charles River, L’Arbresle, France) were
anesthetized and maintained below 1.5% to 2% isoflurane
in 30% oxygen and 70% nitrous oxide using a face mask.
At 0 h, ischemia was induced by inserting an 11-mm
silicone-coated 8-0 filament through the left common
carotid artery into the internal carotid artery (Wiegler
et al, 2008; and references therein). The filament was
withdrawn after 30 mins allowing reperfusion. Regional
cerebral blood flow (rCBF) was measured by laser-Doppler
flowmetry (Periflux 5000, Perimed, Sweden) with a
flexible probe fixed on the skull, 1 mm posteriorly and
6 mm laterally from the bregma. Throughout the entire
operation, rCBF was monitored and maintained within the
target range of 18%±3.5% of the baseline level during
ischemia and 74%±8.5% of the baseline after reperfusion.
On average, 30% of the operated animals did not fulfill the
inclusion criteria (cerebral blood flow below 20% during
ischemia and above 50% after reperfusion) and were
immediately discarded from the study. Throughout surgery
and until awaking, the rectal temperature was maintained
at 371C±0.51C with a temperature control unit (FHC Inc.,
Bowdoinham, ME, USA).
Mice were given 0.025 mg/kg of buprenorphine subcuta-
neously for analgesia at the end of the operation. Once
animals were awake, they were housed in an incubator at
311C. Thereafter, the animals underwent longitudinal MR
studies. More specifically, studies at 3 and 8 h after
ischemia were chosen with regard to the therapeutic
window, in this model, of D-JNKI-1, a neuroprotective
JNK-inhibiting peptide (Borsello et al, 2003), and studies at
24 h after ischemia were performed for lesion identifica-
tion. In addition, nine mice (26 to 37 g) were measured and
served as the healthy control group. To evaluate the effects
of repeated bouts of isoflurane anesthesia (owing to the
repeated MR measurements) on the development of the
striatal lesions (Sicard et al, 2003), five mice (22 to 33 g)
underwent the same MCAO protocol, with no further MR
measurements or isoflurane administration.
Magnetic Resonance Instruments
Magnetic resonance studies were carried out in a horizon-
tal, 14.1-T/26-cm magnet (Magnex Scientific, Abingdon,
UK), with a 12-cm inner-diameter gradient (400 mT/m in
200msecs, minimized eddy currents), interfaced with a
DirectDrive console (Varian Inc., Palo Alto, CA, USA). A
home-built quadrature surface coil with two geometrically
decoupled single-turn loops (12-mm inner diameter),
resonating at 600 MHz radio frequency, was used for radio
frequency transmission and reception at 14.1 T.
In Vivo Magnetic Resonance Imaging/Magnetic
Resonance Spectroscopy of the Ischemic Brain
For the MR studies, animals were maintained anesthetized
with 1% to 2% isoflurane mixed with O2 and placed
stereotaxically into the isocenter of the magnet with two
ear pieces and a bite piece in a holder (RAPID Biomedical
GmbH, Rimpar, Germany). Throughout the entire experi-
ment, the animal was simultaneously monitored for
breathing and temperature through a MR-compatible
monitor system (Model 1025, SA Instruments Inc., Stony
Brook, NY, USA), and rectal temperature was maintained
at approximately 37.01C by circulating warm water.
Briefly, multislice T2-weighted images were acquired
using the fast spin-echo technique (Hennig, 1988), with
effective echo time TEeff = 50 msecs and repetition time
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TR = 6,000 msecs to evaluate the evolution of the ischemic
lesion and locate the volume of interest (VOI), in the left
striatum. Thereafter, all first- and second-order shim terms
over the VOI were altered accordingly using the echo-
planar version of FASTMAP (Mlyna´rik et al, 2006; and
references therein) and resulted in a line width of water
within 30 Hz for 6 to 8mL volumes. Localized 1H-MR
spectra were obtained using the SPECIAL technique, TE/
TR = 2.8/4,000 msecs and 320 averages in combination with
outer volume suppression and VAPOR water suppression
(Mlyna´rik et al, 2006; and references therein).
Determination of Ischemic Lesion Volumes
Animals were killed at either 30 or 48 h after the onset of
focal ischemia, and 20-mm-thick, 720mm distant, coronal
cryostat sections were stained with cresyl violet for
histologic determination of the lesion size. A digitalized
image of the Nissl-stained tissue was obtained under a light
stereomicroscope (Leica MZ16FA). The lesion area was
determined using ImageJ software (NIH, http://rsb.info.
nih.gov/ij/) on both Nissl-stained sections and MRI images.
The infarct volume was calculated by multiplying the sum
of the infarct areas on each section by the spacing distance.
Brain swelling was estimated as % (swelling) in Equation
(1) either on the same images or on MRI images, as
described earlier (Gartshore et al, 1997),
%ðswellingÞ ¼ Areaipsilateral  Areacontralateral
Areacontralateral
100 ð1Þ
where Area is the surface area of the specified region,
indicated by the corresponding subscript.
Quantification and Statistics
The in vivo 1H-MR spectra obtained from each study were
processed as in Tka´cˇ I et al (2007), frequency drift-
corrected, summed and eddy-current compensated using
the water signal from the same VOI. Thereafter, the
absolute quantification was obtained using a linear
combination analysis method, LCModel assuming 80%
brain water content (Tka´cˇ et al, 2007; and references
therein), which has been reported to vary minimally after
transient ischemia in rodents (Bentue-Ferrer et al, 1986;
Mdzinarishvili et al, 2007; Taniguchi et al, 2007). In this
study, all metabolites except macromolecules (Mac) in the
basic set of the LCModel were simulated (Mlynarik et al,
2008), that is alanine (Ala), ascorbate (Asc), aspartate
(Asp), Cr, myo-inositol (myo-Ins), g-aminobutryric acid
(GABA), Glc, Gln, Glu, glycine (Gly), GPC, glutathione
(GSH), Lac, NAA, NAAG, PCho, PCr, phosphatylethanola-
mine (PE), scyllo-inositol (scyllo), and Tau. The spectrum
of Mac was measured in vivo using the inversion recovery
technique with further postprocessing, as described earlier
(Mlynarik et al, 2008; and references therein). Most of the
metabolites were quantified with Cramer–Rao lower
bounds (CRLB) < 35%, which correspond to errors in
metabolite concentrations of < 0.5 mmol/g (Tka´cˇ et al,
2007). Summed concentrations (Glu + Gln, PCr + Cr, GPC +
PCho and NAA + NAAG) and concentration ratios
(Gln/Glu and PCr/Cr) were calculated. As GPC + Cho has
been found to be reduced after ischemia (Kuhmonen et al,
1994) and not all PCho and GPC could be quantified
reliably with satisfactory CRLB (Tka´cˇ et al, 2007), only the
sum of GPC + PCho was evaluated. The percentage changes
were calculated compared with healthy control values
obtained in the same study.
All data were presented as mean±s.d., except when
otherwise specified. Significance was set as P < 0.05 using
unpaired two-tailed Student’s t-test.
Results
In this study, a 30-min transient ischemia resulted in
very reproducible ischemic lesions 1 day after
ischemia located in the ipsilateral striatum (in only
two mice there was additional cortical involvement),
which was detected by both MR images and
histologic determinations (Figure 1). T2-weighted
images showed no observable lesion at 3 h after
ischemia onset (Figure 1B), slight and variable T2-
contrast at 8 h (Figure 1C) and more profound lesions
at 24 h (Figure 1D). The striatal lesion size measured
at 24 h by MRI (18.2±2.5 mm3) was in excellent
agreement with the corresponding Nissl staining at
30 h (16.5±9.3 mm3, Figure 1E) and at 48 h
(20.1±5.2 mm3). All striatal lesions at 24 h were
larger than the VOIs (6 to 8mL) of all the acquired
spectra. To rule out a possible effect of isoflurane
used during NMR measurements on lesion size, five
mice underwent the same MCAO without further
anesthesia and were killed at 48 h. The lesion size of
this group was 18.7±3.2 mm3 and was not different
from the lesions that were measured in the mice that
underwent the MR measurements (P = 0.61).
Brain swelling assessed using Equation (1) corre-
lated well with the published observations (de Castro
Ribeiro et al, 2006), showing a first peak of swelling
directly after ischemia slightly visible at 3 h
(2.4%±1.9%) and a second peak beginning at 30 h
(4.5%±1.5%) and increasing until 48 h (11.4%±
4.2%). There was no swelling in the period between
the two peaks (0.5%±1.1% at 8 h and 0%±1.6% at
24 h), indicating that our metabolite measurements
were not biased by variable water content due to
edema.
Localized 1H-MR spectra acquired from the stria-
tum (a typical example is shown in Figure 2)
presented excellent line widths (12 to 28 Hz), water
suppression and high signal-to-noise ratios (12±3),
which are prerequisites for robust metabolic con-
centration determinations. At 14.1 T, additional
resolved signals, ascribed to Ala, GPC, GABA,
glycine, NAAG and PCho (Mlynarik et al, 2008),
were clearly detected (Figure 2A). Therefore, a
neurochemical profile of 21 metabolites, including
NAAG (0.58±0.12 micromole/g), PCho (0.45±0.12
micromole/g) and scyllo (0.20±0.06 micromole/g),
could be routinely quantified in healthy mouse
striatum, with CRLB mostly within 35% (Table 1).
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This high-quality neurochemical profile obtained at
14.1 T allowed the precise quantification of low-
concentration metabolites.
Noticeable changes were already apparent in the
spectra obtained 3 h after ischemia, such as the clear
reduction in NAA and Glu concentrations and the
increase in Lac and Gln concentrations, as illustrated
in the example in Figure 2B. At later time points,
additional metabolite reductions were readily
observed in the spectra, such as in GABA at 8 h
(Figure 2C), and Ala and myo-Ins at 24 h (Figure 2D).
Lactate concentration remained highly elevated in all
ischemic mice at all time points.
Quantitative analysis confirmed the visually
apparent changes (see above) and additional changes
were detected in the neurochemical profile
(Table 1). With ischemia evolution, these changes
became increasingly significant and involved an
increasing number of metabolites, which are sum-
marized in Table 2. For example, the decrease in
Tau and GSH concentrations became more severe
at 8 h compared with that at 3 h (Table 2). At 24 h,
most metabolites were significantly reduced com-
pared with controls, with the notable exception of
aspartate, Glc, Gln, Lac and NAAG (Table 1). It
is interesting to note that Glc was consistently
detected even in the presence of elevated Lac
concentration.
In addition, increased Gln and reduced Glu con-
tents at 3 h (Table 1) resulted in an increase in the
Gln/Glu ratio (Table 1). At 24 h, the Gln/Glu ratio
returned close to normal, whereas the sum of Glu +
Gln remained constant within the experimental error
(Table 1).
The postischemic evolution differed between meta-
bolites and thus did not correlate with the formation
of edema, as shown in Table 2. In particular, three
neuron-specific metabolites, NAA, Glu and Tau,
were all found to decrease with ischemia evolution.
However, although NAA and Tau concentrations
kept decreasing until 24 h, Glu concentration stabi-
lized after 3 h (Figure 3).
Discussion
This study describes several early metabolic changes
preceding overt changes observed in T2-weighted
Figure 1 T2-weighted images of a control mouse (A) and at different time points after 30 mins MCAO (B: 3 h, C: 8 h, D: 24 h)
showing the evolution of the ischemic lesion in the left MCA territory. (B, C and D) Multislice coronal images acquired with T2-
weighted MR parameters (TE/TR = 50/6,000 msecs, NT = 4) at 3, 8 and 24 h, respectively. The ischemic lesion developed
gradually over time and correlated well after 24 h with the Nissl-stained sections (regions marked with the gray lines) at 30 h (E).
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images. This was possible using a highly reproduci-
ble striatal insult combined with very high magnetic
field MRS techniques performed at 14.1 T. To date,
this is the first in vivo study to measure the
postischemic evolution of the neurochemical profile
in mice.
In the current MCAO model, the T2-weighted
MR images showed highly consistent lesion devel-
Figure 2 Time course of in vivo localized 1H-MR spectra in one ischemic mouse compared with the spectrum of one healthy control.
In the control spectrum (A), respective metabolite assignments are indicated. Quantified changes (Table 1) are marked with specific
orientated arrows (m for increase, k for decrease), with the corresponding metabolite name alongside. For instance, the increase in
Gln at 3 h (B) is indicated by m alongside ‘Gln’. Thereafter, progressively visible changes at 8 h (C) and 24 h (D) are only indicated if
not present at an earlier time point. All spectra (SPECIAL, TE/TR = 2.8/4,000 msecs, NT = 320) were displayed with Gaussian
apodization (gf = 0.11 secs) and scaled relative to the concentration of macromolecules (Mac). Abbreviations: alanine (Ala),
aspartate (Asp), creatine (Cr), myo-inositol (myo-Ins), g-aminobutryric acid (GABA), glutamine (Gln), glutamate (Glu), glycine (Gly),
glycerophoshocholine (GPC), glutathione (GSH), lactate (Lac), N-acetyl-aspartate (NAA), N-acetyl-aspartyl-glutamate (NAAG),
phosphocholine (PCho), phosphocreatine (PCr) phosphatylethanolamine (PE) and taurine (Tau).
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opment in the striatum at 24 h when compared with
lesion volume assessed by Nissl staining (Figure 1).
Excluding the two animals with cortical involvement
did not alter any of the significantly changed
metabolite concentrations (i.e., Glu, Gln, Lac, NAA
and Tau, see Table 1) by more than 6%, and thus was
without significant impact on the conclusions of this
study. In the metabolite concentrations described in
Table 1, the Mac resonances showed a 20% decrease
as early as 3 h after ischemia, which can be
interpreted as a loss of cellular mass, assuming that
the Mac content that is ascribed to cytosolic proteins
(Behar and Ogino, 1993) reflects the cellular mass.
The reduction of 20% of Mac would thus imply an
increase in the water content from 80% to 84%. As
metabolite quantification was performed relative to
tissue water, this could lead to a 4% underestimation
of the metabolite concentrations. However, we
did not detect any macroscopic evidence of brain
swelling. Furthermore, major metabolites, such as
total Cr + PCr, Glu + Gln and myo-Ins, remained at
control levels, which argues against a substantial
increase in tissue water. Therefore, the decrease in
Mac concentration is more likely to be explained by
the degradation of cellular integrity.
Interestingly, prominent and visually apparent
changes could be observed in the MR spectra at an
early stage before apparent changes were detected by
T2-weighted MRI (Figure 2). Most metabolites
showed a significant reduction after focal ischemia,
except Lac and Gln concentrations, which increased,
and Asc, Asp and Glc concentrations, which did not
change significantly. The increased Lac, decreased
NAA and total GPC + PCho, and a variable response
in Ala are in good agreement with the reports
(Hesselbarth et al, 1998; Kuhmonen et al, 1994;
Brulatout et al, 1996).
More specifically, the increase in Lac concen-
tration as early as 3 h after ischemia and its
persistence up to 24 h has already been established
in several studies using different ischemia models
(Berkelbach van der Sprenkel et al, 1988; Hesselbarth
et al, 1998; Thoren et al, 2006; van der Toorn et al,
1994). However, in addition, we found that Lac
accumulated in the presence of normal Glc,
which suggests that the elevated Lac content is not
likely to be due to a persistent oxygen deficiency.
The increased Lac may reflect a change in the
Lac clearance rate relative to the synthesis rate,
possibly mediated by the altered expression of Lac
transporters (Kuhr et al, 1988; Walz and Mukerji
1988). The persistence of high Lac levels days after
ischemia in stroke patients has been proposed
to reflect anerobic glycolysis by macrophages, infil-
trating into the brain after ischemia (Lanfermann
et al, 1995).
Therefore, this study does not indicate a major
energy deficiency after reperfusion, and astrocytes
Table 1 Neurochemical profiles in the striatum of healthy mice, and after 30 min of transient ischemia
Control (8) B3-h (7) B8-h (7) B24-h (10)
Ala 2.8±0.3 3.5±0.6 2.4±0.4 1.4±0.7
Asc 1.5±0.5 1.1±0.55 1.2±0.83 1.0±0.46
Asp 0.9±0.3 1.2±0.55 1.0±0.26 1.2±0.4
Cr 3.8±0.4 3.4±0.6 2.8±0.5 2.7±0.7
Cr+PCr 7.1±0.3 6.9±0.3 5.7±0.5 4.5±0.6
GABA 2.3±0.4 2.0±0.4 1.3±0.4 0.8±0.3
Glc 1.8±0.84 2.4±0.8 1.9±0.6 2.1±0.7
Gln 3.1±0.4 5.2±0.6 5.8±0.7 3.6±0.6
Glu 7.3±0.7 5.0±0.7 5.3±0.4 5.4±0.9
Glu+Gln 10.3±0.9 10.2±0.5 11.1±0.4 9.0±1.0
Gly 1.5±0.4 1.4±0.4 1.4±0.25 1.0±0.5
GPC+PCho 1.3±0.3 0.6±0.2 0.5±0.1 0.6±0.2
GSH 1.4±0.2 1.2±0.3 0.6±0.26 0.4±0.15
myo-Ins 4.3±0.8 4.0±0.4 3.6±0.6 2.2±0.3
myo-Ins+Gly 5.9±0.7 5.4±0.7 4.8±0.9 3.2±0.6
Lac 5.6±1.7 8.3±2.6 10.0±1.6 10.7±3.3
Mac 1.4±0.1 1.1±0.1 1.2±0.1 1.1±0.1
NAA 6.7±0.4 4.7±0.5 3.8±0.5 3.0±0.7
NAA+NAAG 7.2±0.5 5.2±0.6 4.5±0.6 3.5±0.6
NAAG 0.6±0.1 0.6±0.1 0.8±0.2 0.7±0.2
PCr 3.3±0.2 3.5±0.6 2.9±0.5 1.9±0.6
PE 2.3±0.6 1.9±0.6 1.9±0.6 1.3±0.6
Tau 12.9±1.1 11.1±0.7 8.0±1.4 5.2±0.6
Gln/Glu 0.4±0.0 1.1±0.3 1.1±0.2 0.7±0.2
PCr/Cr 0.9±0.1 1.1±0.4 1.1±0.3 0.8±0.3
Ala, alanine; Asc, ascorbate; Asp, aspartate; Cr, creatine; myo-Ins, myo-inositol; GABA, g-aminobutryric acid; Glc, glucose; Gln, glutamine; Glu, glutamate; Gly,
glycine; GPC, glycerophosphocholine; GSH, glutathione; Lac, lactate; Mac, macromolecule; NAA, N-acetyl-aspartate, NAAG, N-acetyl-aspartyl-glutamate;
PCho, phosphocholine; PCr, phosphocreatine; PE, phosphatylethanolamine; Tau, taurine.
All concentrations, except ratios, are in mmol/g. Number of animals is indicated in parentheses. Superscripts indicate a lower number of data points, as
measurements with CRLB > 50% were excluded from the analysis.
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are likely to retain sufficient energy for the uptake of
extracellular Glu to convert into Gln, both of which
are major steps to sustain Glu/Gln homeostasis in
Gln–Glu cycling (Rossi et al, 2007) and require ATP
(Laake et al, 1995). Glu released from neurons after
ischemia, leading to extracellular accumulation and
excitotoxicity (Benveniste et al, 1984), is cleared by
the astrocytes and converted into Gln. The profound
increase in Gln/Glu with the concomitant constant
Gln + Glu suggests that Glu excitotoxicity in reper-
fusion leads to a transient Gln accumulation in
astrocytes.
In normal brain tissue, Glu is mainly located in
neurons (Torp et al, 1991). Therefore, given the
proposed metabolic shift of Glu to glial Gln (Torp
et al, 1991), we would expect a more dramatic
decrease in Glu than in the putative neuronal marker
NAA (Clark, 1998). When compared with changes in
Glu, the reduction of NAA was significantly more
pronounced than that of Glu at 8 h and 24 h after
ischemia. This is surprising, considering that both
Glu and NAA are ascribed to the neuronal compart-
ment and a metabolic conversion of Glu into Gln was
likely. Concurrently, Tau, a putative osmotic regu-
lator ascribed mainly to neurons (Nagelhus et al,
1993; Torp et al, 1991), showed a decrease similar to
that of NAA (Figure 3). Whether the similarity of the
reduction in Tau compared with NAA implies
osmoregulatory properties of NAA (Taylor et al,
1995; Tranberg et al, 2007) remains to be determined.
Our study suggests that NAA might not just reflect
the number of living neurons; rather, gives an
indication of the status of these neurons.
Interestingly, the neurochemical profile of the
present healthy ICR-CD1 mice (Table 1) showed
apparently different metabolic information com-
pared with other strains or species, for example,
lower concentrations of Gln, Glu and Lac compared
with R6/2 and C57 black mice (Tka´cˇ et al, 2007; and
references therein) or higher Lac and Tau concentra-
tions than those of Sprague-Dawley rats (Mlynarik
et al, 2008). This suggests that a knowledge of the
additional metabolic information attainable as
shown in this study likely provides a complementary
insight into various stroke models (Bardutzky et al,
2005).
In addition to differences in mouse strains, it is
possible that the known neuroprotective effect of
isoflurane (Sakai et al, 2007; Sicard et al, 2003) may
have mitigated the extent of the striatal lesion.
Indeed, when the same person performed the
identical MCAO protocol, but under halothane
anesthesia, it resulted in larger lesions (data not
shown). Although isoflurane is known to be neuro-
protective when administered after ischemia (Lee
et al, 2008), the short (2 h) MR measurements
requiring isoflurane anesthesia did not have a
discernible effect on lesion size and extent. It is
therefore remarkable that even under conditions that
might mitigate lesion development, early neuro-
chemical changes were clearly and consistently
discernible and thus are likely to be more pro-
nounced in more severe lesion models.
Thus, it will be of great interest to measure the
effect of neuroprotective agents on such early
metabolic changes and to extend the current ap-
proach to the ischemic penumbra in conjunction
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Ala, alanine; Cr, creatine; myo-Ins, myo-inositol; GABA, g-aminobutryric acid;
Glc, glucose; Gln, glutamine; Glu, glutamate; Gly, glycine; GPC, glycero-
phosphocholine, GSH, glutathione; Lac, lactate; Mac, macromolecule; NAA,
N-acetyl-aspartate, NAAG, N-acetyl-aspartyl-glutamate; PCho, phosphocho-
line; PCr, phosphocreatine; PE, phosphatylethanolamine; Tau, taurine.
The changes are calculated from Table 1 and displayed with specific
orientated arrows (‘m’ as increase and ‘k’ as decrease). The number of ‘*’,
represents statistically significant levels of P = 0.05, 0.02, 0.01, 0.001,
0.0001 and 0.00001.
Figure 3 Relative changes in taurine (Tau), N-acetyl-aspartate
(NAA) and glutamate (Glu) concentrations after ischemia
compared with those in control at 3 h (white bars), 8 h (gray
bars) and 24 h (solid black bars). The error bars represent s.e.m.
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with perfusion and diffusion imaging techniques
(Shen et al, 2004).
We conclude that after transient ischemia, in the
core region of the lesion even if energy metabolism
appears close to normal, allowing for the removal of
excitotoxic extracellular Glu, Lac accumulation and
decreases in 16 metabolites still occur. These early
metabolic changes may provide insights into the
subsequent tissue damage and provide early markers
of lesion evolution. The neurochemical profile can
thus serve as the basis for future experiments to
evaluate neuroprotection or to find markers of
different lesion status in ischemic mice. Moreover,
they can be used to point out potential therapeutic
targets and for early evaluation of neuroprotective
strategies.
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